Cancer letters最新文献_第2页

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies 莫博克替尼拮抗ABCB1和ABCG2表达缺失癌细胞的多药耐药性：体外和体内研究

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-29 DOI: 10.1016/j.canlet.2024.217309

Xing-Duo Dong , Meng Zhang , Qiu-Xu Teng , Zi-Ning Lei , Chao-Yun Cai , Jing-Quan Wang , Zhuo-Xun Wu , Yuqi Yang , Xiang Chen , Huiqin Guo , Zhe-Sheng Chen

{"title":"Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies","authors":"Xing-Duo Dong , Meng Zhang , Qiu-Xu Teng , Zi-Ning Lei , Chao-Yun Cai , Jing-Quan Wang , Zhuo-Xun Wu , Yuqi Yang , Xiang Chen , Huiqin Guo , Zhe-Sheng Chen","doi":"10.1016/j.canlet.2024.217309","DOIUrl":"10.1016/j.canlet.2024.217309","url":null,"abstract":"<div><div>Overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1 and ABCG2, strongly correlates with multidrug resistance (MDR), rendering cancer chemotherapy ineffective. Exploration and identification of novel inhibitors targeting ABCB1 and ABCG2 are necessary to overcome the related MDR. Mobocertinib is an approved EGFR/HER2 inhibitor for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This study demonstrates that mobocertinib can potentially reverse ABCB1- and ABCG2-mediated MDR. Our findings indicate a strong interaction between mobocertinib and these two proteins, supported by its high binding affinity with ABCB1 and ABCG2 models. Through inhibiting the drug efflux function of ABCB1 and ABCG2, mobocertinib facilitates substrate drugs accumulation, thereby re-sensitizing substrate drugs in drug-resistant cancer cells. Additionally, mobocertinib inhibited the ATPase activity of ABCB1 and ABCG2 without changing the expression levels or subcellular localization. In the tumor-bearing mouse model, mobocertinib boosted the antitumor effect of paclitaxel and topotecan, resulting in tumor regression. In summary, our study uncovers a novel potential for repurposing mobocertinib as a dual inhibitor of ABCB1 and ABCG2, and suggests the combination of mobocertinib with substrate drugs as a strategy to counteract MDR.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"607 ","pages":"Article 217309"},"PeriodicalIF":9.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of semaphorins, neuropilins and plexins in cancer progression Semaphorins、neuropilins 和 plexins 在癌症进展中的作用。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-28 DOI: 10.1016/j.canlet.2024.217308

P. Fernández-Nogueira , P. Linzoain- Agos , M. Cueto-Remacha , I. De la Guia-Lopez , L. Recalde-Percaz , A. Parcerisas , P. Gascon , N. Carbó , A. Gutierrez-Uzquiza , G. Fuster , P. Bragado

{"title":"Role of semaphorins, neuropilins and plexins in cancer progression","authors":"P. Fernández-Nogueira , P. Linzoain- Agos , M. Cueto-Remacha , I. De la Guia-Lopez , L. Recalde-Percaz , A. Parcerisas , P. Gascon , N. Carbó , A. Gutierrez-Uzquiza , G. Fuster , P. Bragado","doi":"10.1016/j.canlet.2024.217308","DOIUrl":"10.1016/j.canlet.2024.217308","url":null,"abstract":"<div><div>Progress in understanding nervous system-cancer interconnections has emphasized the functional role of semaphorins (SEMAs) and their receptors, neuropilins (NRPs) and plexins (PLXNs), in cancer progression. SEMAs are a conserved and extensive family of broadly expressed soluble and membrane-associated proteins that were first described as regulators of axon guidance and neural and vascular development. However, recent advances have shown that they can have a dual role in cancer progression, acting either as tumor promoters or suppressors. SEMAs effects result from their interaction with specific co-receptors/receptors NRPs/PLXNs, that have also been described to play a role in cancer progression. They can influence both cancer cells and tumor microenvironment components modulating various aspects of tumorigenesis such as oncogenesis, tumor growth, invasion and metastatic spread or treatment resistance. In this review we focus on the role of these axon guidance signals and their receptors and co-receptors in various aspects of cancer. Furthermore, we also highlight their potential application as novel approaches for cancer treatment in the future.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"606 ","pages":"Article 217308"},"PeriodicalIF":9.1,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase 肿瘤相关巨噬细胞通过过表达胸苷磷酸化酶使消化系统癌症患者对化疗（三氟脲啶/噻嘧啶）产生抗药性。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-23 DOI: 10.1016/j.canlet.2024.217307

Marie Malier , Marie-Hélène Laverriere , Maxime Henry , Malika Yakoubi , Pascale Bellaud , Cécile Arellano , Anthony Sébillot , Fabienne Thomas , Véronique Josserand , Edouard Girard , Gael S. Roth , Arnaud Millet

{"title":"Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing thymidine phosphorylase","authors":"Marie Malier , Marie-Hélène Laverriere , Maxime Henry , Malika Yakoubi , Pascale Bellaud , Cécile Arellano , Anthony Sébillot , Fabienne Thomas , Véronique Josserand , Edouard Girard , Gael S. Roth , Arnaud Millet","doi":"10.1016/j.canlet.2024.217307","DOIUrl":"10.1016/j.canlet.2024.217307","url":null,"abstract":"<div><div>Pyrimidine analogs are part of the first-line chemotherapy regimen for gastrointestinal cancers. Trifluridine combined with tipiracil, a specific thymidine phosphorylase inhibitor, in TAS-102 has recently emerged as a potential alternative in the face of primary or secondary chemoresistance to 5-fluorouracil. Despite its promise, we report that macrophage-specific overexpression of thymidine phosphorylase results in macrophage-induced chemoresistance to TAS-102 that is insensitive to tipiracil inhibition. Furthermore, we illustrate the human-specific nature of this mechanism, as mouse macrophages do not express substantial levels of thymidine phosphorylase, which constrains the applicability of mouse models. To study the importance of macrophages in chemoresistance to trifluridine, we developed a humanized mouse model with tumor-implanted human macrophages and demonstrated their important role in treatment resistance to pyrimidine analogs. Additionally, our findings revealed that macrophages represent a significant source of thymidine phosphorylase expression, comprising over 40 % of the expressing cells, in human colorectal cancer, thereby contributing to chemoresistance.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"606 ","pages":"Article 217307"},"PeriodicalIF":9.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis 骨肉瘤中组蛋白去乙酰化酶上调神经蛋白-1对肺转移至关重要

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-18 DOI: 10.1016/j.canlet.2024.217302

Niveditha Nerlakanti , Jeremy J. McGuire , Ryan T. Bishop , Mostafa M. Nasr , Tao Li , Damon R. Reed , Conor C. Lynch

{"title":"Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis","authors":"Niveditha Nerlakanti , Jeremy J. McGuire , Ryan T. Bishop , Mostafa M. Nasr , Tao Li , Damon R. Reed , Conor C. Lynch","doi":"10.1016/j.canlet.2024.217302","DOIUrl":"10.1016/j.canlet.2024.217302","url":null,"abstract":"<div><div>The lungs represent the most common site of metastasis for osteosarcoma (OS). Despite our advances in developing targeted therapies for treating solid malignancies, broad acting chemotherapies remain the first line treatment for OS. In assaying the efficacy of approved therapeutics for non-OS malignancies, we previously identified the histone deacetylase 1 and 2 (HDAC1 and 2) inhibitor, romidepsin, as effective for the treatment of established lung metastatic OS. Yet, romidepsin has noted toxicities in humans and so here we aimed to define the primary mechanisms through which HDAC1/2 mediate OS progression to identify more selective druggable targets/pathways. Microarray and proteomics analyses of romidepsin treated OS cells revealed a significant suppression of neuropilin-1 (NRP1), a known regulator of cancer cell migration and invasion. Silencing of <em>NRP1</em> significantly reduced OS proliferation, migration, invasion and adhesion <em>in vitro</em>. More strikingly, <em>in vivo</em>, reduced NRP1 expression significantly mitigated the lung metastatic potential of OS in two independent models (K7M2 and SAOS-LM7). Mechanistically, our data point to NRP1 mediating this effect via the down regulation of migration machinery, namely SRC, FAK and ROCK1 expression/activity, that is in part, related to NRP1 interaction with integrin beta 1 (ITGB1). In summary, our data indicate that romidepsin down regulation of NRP1 significantly mitigates the ability of OS cells to seed the lung and establish metastases, and that targeting NRP1 or its effectors with selective inhibitors may be a viable means with which to prevent this deadly aspect of the disease.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"606 ","pages":"Article 217302"},"PeriodicalIF":9.1,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional diversity and regulation of IL-9-producing T cells in cancer immunotherapy 癌症免疫疗法中产生 IL-9 的 T 细胞的功能多样性和调节。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-18 DOI: 10.1016/j.canlet.2024.217306

Muhammad Kalim , Rui Jing , Wei Guo, Hui Xing, Yong Lu

引用次数: 0

The pharmacogenomic and immune landscape of snoRNAs in human cancers 人类癌症中 snoRNAs 的药物基因组学和免疫格局。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-18 DOI: 10.1016/j.canlet.2024.217304

Runhao Wang , Chengxuan Chen , Yuan Liu , Mei Luo , Jingwen Yang , Yamei Chen , Lifei Ma , Liuqing Yang , Chunru Lin , Lixia Diao , Leng Han

{"title":"The pharmacogenomic and immune landscape of snoRNAs in human cancers","authors":"Runhao Wang , Chengxuan Chen , Yuan Liu , Mei Luo , Jingwen Yang , Yamei Chen , Lifei Ma , Liuqing Yang , Chunru Lin , Lixia Diao , Leng Han","doi":"10.1016/j.canlet.2024.217304","DOIUrl":"10.1016/j.canlet.2024.217304","url":null,"abstract":"<div><div>Small nucleolar RNAs (snoRNAs) are a class of non-coding RNAs primarily known for their role in the chemical modification of other RNAs. Recent studies suggested that snoRNAs may play a broader role in anti-cancer treatments such as targeted therapies and immunotherapies. Despite these insights, the comprehensive landscape of snoRNA associations with drug response and immunotherapy outcomes remains unexplored. In this study, we identified 79,448 and 75,185 associations between snoRNAs and drug response using data from VAEN and CancerRxTissue, respectively. Additionally, we discovered 29,199 associations between snoRNAs and immune checkpoint genes and 47,194 associations between snoRNAs and immune cell infiltrations. Sixteen snoRNAs were significantly correlated with immunotherapy objective response rate (ORR), and 92 snoRNAs showed significantly differential expression between cancers with high and low ORR. Furthermore, we identified 17 snoRNAs with significantly differential expression between cancer types with high and low immune-related adverse event (irAE) reporting odds ratio (ROR). Several snoRNAs, such as SNORD92, and SNORD83B, may represent promising biomarkers or therapeutic targets that needs further investigation. To facilitate further research, we developed a user-friendly portal, Pharmacogenomic and Immune Landscape of SnoRNA (PISNO, <span><span>https://hanlaboratory.com/PISNO/</span><svg><path></path></svg></span>), enabling researchers to visualize, browse, and download multi-dimensional data. This study highlights the potential of snoRNAs as biomarkers or therapeutic targets, paving the way for more effective and personalized anti-cancer treatments.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"605 ","pages":"Article 217304"},"PeriodicalIF":9.1,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models CD94 缺乏或阻断可释放小鼠和人源化小鼠模型的抗肿瘤免疫力。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-17 DOI: 10.1016/j.canlet.2024.217305

Jiarui Li , Xianwei Wang , Guoshuai Cao , Yuwei Wu , Ming Cheng , Yawen Chen , Haoyu Sun , Rui Sun , Hui Peng , Zhigang Tian

{"title":"CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models","authors":"Jiarui Li , Xianwei Wang , Guoshuai Cao , Yuwei Wu , Ming Cheng , Yawen Chen , Haoyu Sun , Rui Sun , Hui Peng , Zhigang Tian","doi":"10.1016/j.canlet.2024.217305","DOIUrl":"10.1016/j.canlet.2024.217305","url":null,"abstract":"<div><div>NKG2 family members have emerged as promising targets in tumor immunotherapy. CD94 can dimerize with both inhibitory and activating NKG2 proteins, while the overall effect and value of targeting CD94 on anti-tumor immunity are unclear. Here, it is shown that the expression of CD94 is upregulated on tumor-infiltrating natural killer (NK) cells and CD8<sup>+</sup> T cells, and is related to their exhausted characteristics. Tumor-bearing CD94 knockout (CD94-KO) mice exhibit delayed tumor growth, decreased lung metastases, and prolonged survival. Single cell RNA-seq reveals a remodeled tumor microenvironment in CD94-KO mice, with a reduction in immunosuppressive cells and an increase in anti-tumor immune cells. Moreover, NK cells and CD8<sup>+</sup> T cells become proliferative and strongly tumoricidal in CD94-KO mice, thus contributing to the tumor inhibition effect of CD94 deficiency. Treatment with a humanized anti-CD94 blocking antibody (h15C10) alone, in tumor-bearing humanized mouse, delays tumor progression, and improves the therapeutic efficacy of PD-L1 blockade through combination therapy. Our study indicates that CD94 may work as a candidate target in checkpoint immunotherapy.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"605 ","pages":"Article 217305"},"PeriodicalIF":9.1,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

LncRNAs and the cancer epigenome: Mechanisms and therapeutic potential LncRNAs 与癌症表观基因组：机制与治疗潜力》。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-16 DOI: 10.1016/j.canlet.2024.217297

Revathy Nadhan , Ciro Isidoro , Yong Sang Song , Danny N. Dhanasekaran

引用次数: 0

The eIF3a translational control axis in the Wnt/β-catenin signaling pathway and colon tumorigenesis Wnt/β-catenin信号通路中的eIF3a翻译控制轴与结肠肿瘤发生。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-15 DOI: 10.1016/j.canlet.2024.217303

Zizheng Dong, Anuj Ojha, Lincoln Barlow, Liyun Luo, Jing-Yuan Liu, Jian-Ting Zhang

{"title":"The eIF3a translational control axis in the Wnt/β-catenin signaling pathway and colon tumorigenesis","authors":"Zizheng Dong, Anuj Ojha, Lincoln Barlow, Liyun Luo, Jing-Yuan Liu, Jian-Ting Zhang","doi":"10.1016/j.canlet.2024.217303","DOIUrl":"10.1016/j.canlet.2024.217303","url":null,"abstract":"<div><div>Translational initiation in protein synthesis is an important regulatory step in gene expression and its dysregulation may result in diseases such as cancer. Translational control by eIF4E/4<em>E</em>-BP has been well studied and contributes to mTOR signaling in various biological processes. Here, we report a novel translational control axis in the Wnt/β-catenin signaling pathway in colon tumorigenesis by eIF3a, a Yin-Yang factor in tumorigenesis and prognosis. We show that eIF3a expression is upregulated in human colon cancer tissues, pre-cancerous adenoma polyps, and associates with β-catenin level and APC mutation in human samples, and that eIF3a overexpression transforms intestinal epithelial cells. We also show that eIF3a expression is regulated by the Wnt/β-catenin signaling pathway with an active TCF/LEF binding site in its promoter and that eIF3a knockdown inhibits APC mutation-induced spontaneous colon tumorigenesis in APC<sup>min/+</sup> mice. Together, we conclude that eIF3a upregulation in colon cancer is due to APC mutation and it participates in colon tumorigenesis by adding a translational control axis in the Wnt/β-catenin signaling pathway and that it can serve as a potential target for colon cancer intervention.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"605 ","pages":"Article 217303"},"PeriodicalIF":9.1,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC 对糖皮质激素相关基因的评估显示 GPD1 是 CRPC 的治疗靶点和 1-磷酸鞘磷脂代谢的调节器。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-15 DOI: 10.1016/j.canlet.2024.217286

Ren Liu , Zhihao Zou , Zhengrong Zhang , Huichan He , Ming Xi , Yingke Liang , Jianheng Ye , Qishan Dai , Yongding Wu , Huijing Tan , Weide Zhong , Zongren Wang , Yuxiang Liang

{"title":"Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC","authors":"Ren Liu , Zhihao Zou , Zhengrong Zhang , Huichan He , Ming Xi , Yingke Liang , Jianheng Ye , Qishan Dai , Yongding Wu , Huijing Tan , Weide Zhong , Zongren Wang , Yuxiang Liang","doi":"10.1016/j.canlet.2024.217286","DOIUrl":"10.1016/j.canlet.2024.217286","url":null,"abstract":"<div><div>Prostate cancer (PCa) is an androgen-dependent disease, with castration-resistant prostate cancer (CRPC) being an advanced stage that no longer responds to androgen deprivation therapy (ADT). Mounting evidence suggests that glucocorticoid receptors (GR) confer resistance to ADT in CRPC patients by bypassing androgen receptor (AR) blockade. GR, as a novel therapeutic target in CRPC, has attracted substantial attention worldwide. This study utilized bioinformatic analysis of publicly available CRPC single-cell data to develop a consensus glucocorticoid-related signature (Glu-sig) that can serve as an independent predictor for relapse-free survival. Our results revealed that the signature demonstrated consistent and robust performance across seven publicly accessible datasets and an internal cohort. Furthermore, our findings demonstrated that glycerol-3-phosphate dehydrogenase 1 (GPD1) in Glu-sig can significantly promote CRPC progression by mediating the cell cycle pathway. Additionally, GPD1 was shown to be regulated by GR, with the GR antagonist mifepristone enhancing the anti-tumorigenic effects of GPD1 in CRPC cells. Mechanistically, targeting GPD1 induced the production of sphingosine 1-phosphate (S1P) and enhanced histone acetylation, thereby inducing the transcription of p21 that involved in cell cycle regulation. In conclusion, Glu-sig could serve as a robust and promising tool to improve the clinical outcomes of PCa patients, and modulating the GR/GPD1 axis that promotes tumor growth may be a promising approach for delaying CRPC progression.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"605 ","pages":"Article 217286"},"PeriodicalIF":9.1,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0